Advances in Breast Cancer Management, 2nd edition
The optimal management of breast cancer patients relies on the expertise of a team of medical specialists including radiologists, surgeons, radiation therapists and medical oncologists. Much of the progress in breast cancer management made over the last several years reflects the translation of observations made in the laboratory to the clinic. Critically evaluating the impact of new treatment approaches relies on a commitment to well-designed clinical trials. In this volume, Advances in Breast Cancer Management, a renowned group of breast cancer experts have been asked to provide their perspective on management issues that directly effect patients on a day-to-day basis. Dr. Melody Cobleigh discusses the consequences of estrogen deprivation and the ways of ameliorating secondary symptoms and the potential long-term morbidity. Drs. Haigh and Guiliano review the sentinel lymph node biopsy technique including results from their extensive experience. Dr. Abram Recht places into perspective the potential benefit of post-mastectomy radiotherapy and reviews recent trials that address this issue. Dr. Dennis Slamon takes from us from the laboratory to the clinic in explaining the development of Herceptin as a paradigm for therapy targeted to specific molecular characteristics of breast cancer tumor cells. Drs. Nieto, Shpall, Crump and Pritchard offer different perspectives on the future of high-dose chemotherapy with stem cell transplantation as a treatment for breast cancer patients. Drs.
Comentarios de la gente - Escribir un comentario
No encontramos ningún comentario en los lugares habituales.
Managing Menopausal Problems
Sentinel Lymphadenectomy In Node Negative Breast Cancer
The Molecular and Cellular Biology of HER2neu Gene AmplificationOverexpression and the Clinical Development of Herceptin Trastuzumab Thera...
Highdose Chemotherapy for Breast Cancer
High Dose Therapy with Stem Cell Support for Breast Cancer The Jury Is Still Out
Otras ediciones - Ver todas
adjuvant chemotherapy adjuvant tamoxifen adjuvant therapy advanced breast cancer ALND anthracycline antibody autologous bone marrow benefit biopsy breast cancer patients Cancer Res carboplatin carcinoma cisplatin clinical trials compared cycles cyclophosphamide disease docetaxel dose intensity doxorubicin duration early breast cancer endometrial cancer epirubicin evaluation factors fluorouracil HDCT HER2 Herceptin high-dose chemotherapy high-dose therapy high-risk hormone incidence increase lumpectomy lymph nodes mastectomy median follow-up menopausal metastatic breast cancer methotrexate mortality Natl Cancer Inst negative node-negative node-positive Oncology operable breast cancer osteoporosis outcome overall survival Overview analysis paclitaxel patients receiving phase placebo PMRT polychemotherapy positive nodes postmenopausal postmenopausal women premenopausal preoperative chemotherapy primary breast cancer Proc Am Soc prognostic Proportional Risk Reduction radiotherapy raloxifene randomized trial recurrence regimens relapse replacement therapy risk of breast sentinel node SLND Soc Clin Oncol STAMP-I standard-dose stem cell stem cell support surgery systemic therapy tamoxifen thiotepa treatment tumor